Literature DB >> 22696664

Complement inhibition to treat myocardial infarction?

Bernhard Gerber1, Tatiana Kyburz, Walter H Reinhart, Piero O Bonetti, Georg Stussi.   

Abstract

The authors describe the case of a middle-aged women who presented with an acute myocardial infarction due to thrombotic occlusion of angiographically normal coronary arteries. Coronary thrombosis was caused by a hypercoagulable state related to a haemolytic crisis of paroxysmal nocturnal haemoglobinuria and the patient was treated conservatively with antithrombotic agents. The clinical course was complicated by both severe bleeding and thrombotic complications and the patient eventually died of a massive intracerebral haemorrhage. The rapid occurrence of complications inhibited a timely administration of a specific treatment for complement-mediated haemolysis (eculizumab).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22696664      PMCID: PMC3083014          DOI: 10.1136/bcr.01.2011.3701

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gerard Socié; Petra Muus; Alexander Röth; Jeffrey Szer; Modupe O Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

2.  Characteristics and prognosis of myocardial infarction in patients with normal coronary arteries.

Authors:  P Ammann; S Marschall; M Kraus; L Schmid; W Angehrn; R Krapf; H Rickli
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

3.  The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis.

Authors:  T Miyata; J Takeda; Y Iida; N Yamada; N Inoue; M Takahashi; K Maeda; T Kitani; T Kinoshita
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

4.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

5.  Eculizumab for paroxysmal nocturnal haemoglobinuria.

Authors:  Charles Parker
Journal:  Lancet       Date:  2009-01-12       Impact factor: 79.321

6.  Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  T Miyata; N Yamada; Y Iida; J Nishimura; J Takeda; T Kitani; T Kinoshita
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

7.  Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeffrey Szer; Robert A Brodsky; Anita Hill; Gerard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young
Journal:  Blood       Date:  2007-08-16       Impact factor: 22.113

8.  Natural history of paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; S M Lewis; M Bessler; L Luzzatto; J V Dacie
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

9.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.

Authors:  J Takeda; T Miyata; K Kawagoe; Y Iida; Y Endo; T Fujita; M Takahashi; T Kitani; T Kinoshita
Journal:  Cell       Date:  1993-05-21       Impact factor: 41.582

10.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

View more
  1 in total

1.  Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report.

Authors:  Anne Quinquenel; Quentin Maestraggi; Carinne Lecoq-Lafon; Peffault de Latour Régis; Alain Delmer; Amélie Servettaz
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.